We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aerie's (AERI) Q1 Loss Wider Than Expected, Revenues Miss
Read MoreHide Full Article
Aerie Pharmaceuticals incurred a loss of 72 cents per share in the first quarter, wider than the Zacks Consensus Estimate of a loss of 69 cents but narrower than the year-ago loss of 84 cents.
Revenues came in at $23 million, which increased from $20.3 million in the year-ago quarter but missed the Zacks Consensus Estimate by 1.64%. Total revenues came from sales of two approved drugs — Rhopressa and Rocklatan.
The stock has rallied 24.6% so far this year against the industry’s loss of 10.9%.
Quarter in Detail
Wholesaler shipments totaled 257,000 bottles in the quarter under review, down from 307,000 bottles in the previous quarter.
We remind investors that the company’s first drug, Rhopressa (netarsudil ophthalmic solution), has been approved for the reduction of elevated intraocular pressure (“IOP”) in patients with open-angle glaucoma or ocular hypertension. Aerie’s second drug, Rocklatan, a once-daily, quadruple-action, fixed-dose combination of Rhopressa and Pfizer’s (PFE - Free Report) Xalatan, has been approved to reduce elevated IOP in patients with open-angle glaucoma or ocular hypertension.
Rhopressa currently has commercial coverage for 90% of lives and market access for 89% of lives covered under Medicare Part D plans. Commercial coverage for Rocklatan represents 89% of covered lives.
Total operating expenses (excluding stock-based compensation expenses) in the reported quarter were $42.2 million, down from the year-ago quarter’s $48.1 million.
Aerie Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Aerie’s phase IIb study for its dry eye product candidate, AR-15512, continues to progress. The company currently expects top-line results from this study, COMET-1, in the third quarter of 2021. The study was initiated in October 2020 and is powered as a phase III study.
Aerie continues to evaluate the clinical and regulatory pathways for phase III studies on AR-1105 (dexamethasone steroid implant) in both the U.S. and European markets.
Meanwhile, Investigational New Drug Application (IND)-enabling preclinical studies are underway for AR-14034 SR, a sustained-release implant containing the pan-VEGF inhibitor, axitinib, formulated in a unique bio-erodible polymer blend.
The first-in-human clinical trial on AR-13503 SR (Rho kinase and protein kinase C inhibitor sustained-release implant) continues to progress. Aerie currently expects to complete the dose-escalation safety evaluation with the current implant design in the first quarter of 2022.
Corcept’s earnings estimates have moved up 8 cents for 2021 in the past 90 days.
Repligen’s earnings estimates have increased 25 cents for 2021 in the past 90 days.
Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020 Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Image: Bigstock
Aerie's (AERI) Q1 Loss Wider Than Expected, Revenues Miss
Aerie Pharmaceuticals incurred a loss of 72 cents per share in the first quarter, wider than the Zacks Consensus Estimate of a loss of 69 cents but narrower than the year-ago loss of 84 cents.
Revenues came in at $23 million, which increased from $20.3 million in the year-ago quarter but missed the Zacks Consensus Estimate by 1.64%. Total revenues came from sales of two approved drugs — Rhopressa and Rocklatan.
The stock has rallied 24.6% so far this year against the industry’s loss of 10.9%.
Quarter in Detail
Wholesaler shipments totaled 257,000 bottles in the quarter under review, down from 307,000 bottles in the previous quarter.
We remind investors that the company’s first drug, Rhopressa (netarsudil ophthalmic solution), has been approved for the reduction of elevated intraocular pressure (“IOP”) in patients with open-angle glaucoma or ocular hypertension. Aerie’s second drug, Rocklatan, a once-daily, quadruple-action, fixed-dose combination of Rhopressa and Pfizer’s (PFE - Free Report) Xalatan, has been approved to reduce elevated IOP in patients with open-angle glaucoma or ocular hypertension.
Rhopressa currently has commercial coverage for 90% of lives and market access for 89% of lives covered under Medicare Part D plans. Commercial coverage for Rocklatan represents 89% of covered lives.
Total operating expenses (excluding stock-based compensation expenses) in the reported quarter were $42.2 million, down from the year-ago quarter’s $48.1 million.
Aerie Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Aerie Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Aerie Pharmaceuticals, Inc. Quote
Recent Updates
Aerie’s phase IIb study for its dry eye product candidate, AR-15512, continues to progress. The company currently expects top-line results from this study, COMET-1, in the third quarter of 2021. The study was initiated in October 2020 and is powered as a phase III study.
Aerie continues to evaluate the clinical and regulatory pathways for phase III studies on AR-1105 (dexamethasone steroid implant) in both the U.S. and European markets.
Meanwhile, Investigational New Drug Application (IND)-enabling preclinical studies are underway for AR-14034 SR, a sustained-release implant containing the pan-VEGF inhibitor, axitinib, formulated in a unique bio-erodible polymer blend.
The first-in-human clinical trial on AR-13503 SR (Rho kinase and protein kinase C inhibitor sustained-release implant) continues to progress. Aerie currently expects to complete the dose-escalation safety evaluation with the current implant design in the first quarter of 2022.
Zacks Rank & Stocks to Consider
Aerie currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the healthcare sector include Corcept Therapeutics (CORT - Free Report) and Repligen Corporation (RGEN - Free Report) , both carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Corcept’s earnings estimates have moved up 8 cents for 2021 in the past 90 days.
Repligen’s earnings estimates have increased 25 cents for 2021 in the past 90 days.
Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020 Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2021 today >>